Table 2.
Nucleoside drugs | MMC group (n = 31) | “TQD” group (n = 65) | “TTK” group (n = 36) |
Not using nucleoside drugs | 21 (67.74) | 55 (84.62) | 27 (75.00) |
Using nucleoside drugs | 10 (32.26) | 10 (15.38) | 9 (25.00) |
Lamivudine | 12 (38.71) | 30 (46.15) | 12 (33.33) |
Adefovir | 0 (0.00) | 5 (7.69) | 4 (11.11) |
Telbivudine | 2 (6.45) | 6 (9.23) | 1 (2.78) |
Entecavi | 6 (19.35) | 12 (18.46) | 5 (13.89) |
Lamivudine combined with adefovir | 1 (3.23) | 1 (1.54) | 5 (13.89) |
Entecavir combined with adefovir | 0 (0.00) | 1 (1.54) | 0 (0.00) |
There was no difference among the three groups in using nucleoside drugs in the study (P = 0.153).